Volume 10, Number 6—June 2004
Dispatch
SARS and Common Viral Infections
Janice K. Louie*†1
, Jill K. Hacker*1, Jennifer Mark*, Shilpa S. Gavali*, Shigeo Yagi†, Alex Espinosa†, David P. Schnurr†, Cynthia K. Cossen†, Erin R. Isaacson†, Carol A. Glaser†, Marc Fischer‡, Arthur L. Reingold†, Duc J. Vugia*†, and for the Unexplained DeathsCritical Illnesses Working Group
, Jill K. Hacker*1, Jennifer Mark*, Shilpa S. Gavali*, Shigeo Yagi†, Alex Espinosa†, David P. Schnurr†, Cynthia K. Cossen†, Erin R. Isaacson†, Carol A. Glaser†, Marc Fischer‡, Arthur L. Reingold†, Duc J. Vugia*†, and for the Unexplained DeathsCritical Illnesses Working GroupTable 1
Respiratory testing algorithma
| Respiratory specimens | Serologic testingb |
|---|---|
| Viral culture | Acute-phase serum specimens: IgM |
| Polymerase chain reaction | Chlamydia spp. |
| Influenza A | Mycoplasma pneumoniae |
| Influenza B | Paired serum specimens: IgG |
| Respiratory syncytial virus | Chlamydia spp. |
| Parainfluenza virus types 1–4 | M. pneumoniae |
| Human metapneumovirus | Influenza A and B |
| Coronavirus OC43 and 229E | Respiratory syncytial virus |
| Adenovirus | Parainfluenza virus types 2–4 |
| Picornavirus | Adenovirus |
| SARS-CoV | SARS-CoV |
aIg, immunoglobulin; SARS-CoV, severe acute respiratory syndrome–associated coronavirus.
bAll serologic assays were in-house enzyme immunoassays (15), except for the Meridian IgM assay for M. pneumoniae (Meridian Bioscience, Inc., Cincinnati, OH) and enzyme-linked immunosorbent assay of the Centers for Disease Control and Prevention for SARS-CoV
